NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY

摘要 本应用程序中描述的研究议程的总体目标是将Cofar定位为 食物过敏研究的国际领先者，包括疾病的最佳特征和 开发下一代治疗方法。下一个Cofar将把食物过敏研究带入新的 具有尖端临床和机制研究的高地，专注于疾病表型和新方法 到预防和治疗。研究议程将首先以尽可能好的科学为基础， 但是，为了最大限度地提高生产率，我们还需要明智地进行规划，以便能够将所有可用的资源用于 他们的最大能力。因此，研究议程将需要仔细选择和阶段性地基于 不仅基于它们推动这一领域的潜力，而且还仔细考虑了其他新的治疗方法 这可能正在开发中，以及一项研究如何为下一项研究提供信息。最后，提出了总体研究策略。 还需要平衡SACCC和联合体中每个CRU的工作负荷。 该计划的三个主要目标是：1)迅速实施食物过敏登记研究，将提供 充分描述大量患者的特征和表型，确定真实的反应率， 并作为临床试验的招募来源；2)开发和实施一种新的、尖端的方案 使用DNA-LAMP疫苗治疗花生过敏的食物过敏；以及3)选择和 制定其他议定书以纳入该联合体，特别是与其他有希望的办法有关 治疗或预防方面的发展。预计至少3个协议，包括这两个 临床试验和非干预性研究将在七年的资助期内启动和完成， 根据每项研究的规模、持续时间和复杂性，这可能会增加到5个甚至6个方案。在……里面 此外，该议程将努力将生物标志基金和机会基金分别纳入 COFAR协议。如果成功，这项研究议程将不仅定义Cofar的未来7年，而且还将 为下一个十年的食物过敏研究搭建平台(S)。

Summary The overarching goal of the research agenda described in this application is to position CoFAR as the international leader in the study of food allergy, including optimal characterization of the disease and development of the next generation of treatments. This next CoFAR will bring food allergy research to new heights with cutting edge clinical and mechanistic studies focused on disease phenotypes and novel approaches to prevention and treatment. The research agenda will be based first and foremost on the best possible science, but to maximize productivity we will also need to plan judiciously so that all available resources can be used to their utmost capacity. Therefore, the research agenda will need to carefully select and stage protocols based not just on their potential to advance the field, but also with careful consideration regarding other novel treatments that may be under development, and how one study may inform the next. Finally, the overall research strategy will also need to balance the work load of the SACCC and each CRU in the consortium. The three major aims of this program are to: 1) rapidly implement a food allergy registry study that will provide the means to fully characterize and phenotype a large population of patients, determine true rates of reactions, and serve as a recruitment source for clinical trials; 2) develop and implement a novel, cutting edge protocol for the treatment of food allergy using a DNA-LAMP vaccine for the treatment of peanut allergy; and 3) choose and develop additional protocols for inclusion in the consortium, especially related to other promising approaches in development for either treatment or prevention. It is anticipated that a minimum of 3 protocols, including both clinical trials and non-interventional studies, will be initiated and completed over the seven-year funding period, and this could rise to 5 or even 6 protocols depending on the size, duration, and complexity of each study. In addition, the agenda will work to fully integrate the Biomarker Facility and the Opportunity Fund into each of the CoFAR protocols. If successful, this research agenda will define not just the next 7 years of CoFAR, but will also establish the platform for the next decade(s) of food allergy research.